Devices
Read Time: 2 mins

98/Cardiac implantable electronic device infections: multicentre validation of a novel risk score and its cost–utility implications for antimicrobial envelope use

Published Online: October 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr98
Authors: E Maclean (Presenting Author) – St Bartholomew’s Hospital, London; K Mahtani – St. Bartholomew’s Hospital, London; S Honarbakhsh – St. Bartholomew’s Hospital, London; C Butcher – St. Bartholomew’s Hospital, London; N Ahluwalia – St. Bartholomew’s Hospital, London; ASC Dennis – St. Bartholomew’s Hospital, London; P Waddingham – St. Bartholomew’s Hospital, London; A Creta – St. Bartholomew’s Hospital, London; M Finlay – St. Bartholomew’s Hospital, London; M Elliott – St. Thomas’ Hospital, London; V Mehta – St. Thomas’ Hospital, London; N Wijesuriya – St. Thomas’ Hospital, London; O Shaikh – Royal Papworth Hospital, Cambridge; M Zaw – Royal Papworth Hospital, Cambridge; CN Ranmuthu – Royal Papworth Hospital, Cambridge; CR Ranmuthu – Royal Papworth Hospital, Cambridge; RJ Schilling – St. Bartholomew’s Hospital, London; PD Lambiase – St. Bartholomew’s Hospital, London; MJ Earley – St. Bartholomew’s Hospital, London; P Moore – St. Bartholomew’s Hospital, London; A Muthumala – St. Bartholomew’s Hospital, London; S Sporton – St. Bartholomew’s Hospital, London; RJ Hunter – St. Bartholomew’s Hospital, London; C Rinaldi – St. Thomas’ Hospital, London; JM Behar – St. Thomas’ Hospital, London; C Martin – Royal Papworth Hospital, Cambridge; C Monkhouse – St. Bartholomew’s Hospital, London; A Chow – St. Bartholomew’s Hospital, London
Quick Links:
Article
Article Information
Article:

Introduction: Antimicrobial envelopes reduce the incidence of cardiac implantable electronic device (CIED) infections; however, patient selection strategies are poorly defined and cost–utility data are limited.

Methods: In a preliminary internal analysis, we examined the factors associated with infection for all transvenous CIED implants, generator changes and non-infected lead interventions at a single tertiary centre from 2016 to 2019. The primary outcome was hospitalisation for device infection within 12 months. We subsequently developed a novel risk score (BLISTER) and, in a multicentre validation cohort, compared prognostic utility versus the PADIT score. Finally, both scores were tested as gatekeepers in cost–utility modelling of the TYRX antimicrobial envelope; quality-adjusted life-year (QALY) increments were extrapolated from analysis of EQ-5D-3L data for all UK patients enrolled in the WRAP-IT trial.

Results: A total of 6,035 patients underwent 7,383 procedures; CIED infection occurred in 59 individuals (0.8%). In addition to the PADIT score constituents, lead extraction (HR 3.3 [1.9–6.1]; p<0.0001), C-reactive protein >50 mg/L (HR 3.0 [1.4–6.4]; p=0.005), re-intervention within 2 years (HR 10.1 [5.6–17.9]; p<0.0001), and procedure duration over 2 hours (HR 2.6 [1.6–4.1]; p=0.001) were independent predictors of infection, and were incorporated into the novel BLISTER score. In a validation cohort comprising 2,701 additional patients from three tertiary centres, BLISTER demonstrated superior prognostic utility versus PADIT (AUC 0.83 vs 0.73; p=0.01). The optimum cost–utility model assigned TYRX envelopes to all patients with a BLISTER score ≥6, and predicted a reduction in infections (0.55% versus 0.8%; p=0.033; number needed to treat 63) with a cost per QALY gained of £24,581.

Conclusions: The BLISTER score was a powerful predictor of infection in a heterogeneous CIED population and may facilitate cost-effective TYRX envelope allocation.

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72